
==== Front
Inflamm Regen
Inflamm Regen
Inflammation and Regeneration
1880-9693
1880-8190
BioMed Central London

351
10.1186/s41232-024-00351-4
Review
Proteomics of blood extracellular vesicles in inflammatory respiratory diseases for biomarker discovery and new insights into pathophysiology
http://orcid.org/0000-0002-8625-7899
Kawasaki Takahiro tkawasaki@imed3.med.osaka-u.ac.jp

123
Takeda Yoshito yoshito@imed3.med.osaka-u.ac.jp

1
Kumanogoh Atsushi 123456
1 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Osaka Japan
2 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Department of Immunopathology, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka Japan
3 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Center for Infectious Diseases for Education and Research (CiDER), Osaka University, Suita, Osaka Japan
4 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka Japan
5 grid.136593.b 0000 0004 0373 3971 Japan Agency for Medical Research and Development – Core Research for Evolutional Science and Technology (AMED–CREST), Osaka University, Suita, Osaka Japan
6 https://ror.org/035t8zc32 grid.136593.b 0000 0004 0373 3971 Center for Advanced Modalities and DDS (CAMaD), Osaka University, Osaka, Japan
18 9 2024
18 9 2024
2024
44 389 7 2024
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Inflammatory respiratory diseases, such as interstitial lung disease (ILD), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), and respiratory infections, remain significant global health concerns owing to their chronic and severe nature. Emerging as a valuable resource, blood extracellular vesicles (EVs) offer insights into disease pathophysiology and biomarker discovery in these conditions.

Main body

This review explores the advancements in blood EV proteomics for inflammatory respiratory diseases, highlighting their potential as non-invasive diagnostic and prognostic tools. Blood EVs offer advantages over traditional serum or plasma samples. Proteomic analyses of blood EVs have revealed numerous biomarkers that can be used to stratify patients, predict disease progression, and identify candidate therapeutic targets. Blood EV proteomics has identified proteins associated with progressive fibrosis in ILD, offering new avenues of treatment. In BA, eosinophil-derived EVs harbor biomarkers crucial for managing eosinophilic inflammation. Research on COPD has also identified proteins that correlate with lung function. Moreover, EVs play a critical role in respiratory infections such as COVID-19, and disease-associated proteins are encapsulated. Thus, proteomic studies have identified key molecules involved in disease severity and immune responses, underscoring their role in monitoring and guiding therapy.

Conclusion

This review highlights the potential of blood EV proteomics as a non-invasive diagnostic and prognostic tool for inflammatory respiratory diseases, providing a promising avenue for improved patient management and therapeutic development.

Keywords

Interstitial lung disease
Bronchial asthma
Chronic obstructive pulmonary disease
Respiratory infections
Blood extracellular vesicles
Proteomics
http://dx.doi.org/10.13039/501100002770 Cabinet Office, Government of Japan http://dx.doi.org/10.13039/100009619 Japan Agency for Medical Research and Development JP223fa627002 Kumanogoh Atsushi http://dx.doi.org/10.13039/501100001691 Japan Society for the Promotion of Science 24K19241 JP19K08650 22K08283 JP18H05282 Kawasaki Takahiro Takeda Yoshito Kumanogoh Atsushi http://dx.doi.org/10.13039/100020050 Japan Intractable Diseases Research Foundation 2023B02 Kawasaki Takahiro http://dx.doi.org/10.13039/501100009098 Japanese Respiratory Society http://dx.doi.org/10.13039/100008732 Uehara Memorial Foundation http://dx.doi.org/10.13039/100019085 Japanese Respiratory Foundation the All-Osaka U Research in ‘The Nippon Foundation–Osaka University Project for Infectious Disease Prevention’issue-copyright-statement© Japanese Society of Inflammation and Regeneration 2024
==== Body
pmcBackground

Inflammatory respiratory diseases, including interstitial lung disease (ILD), bronchial asthma (BA), chronic obstructive pulmonary disease (COPD), and other infectious diseases, are significant global health concerns. Although nonmalignant, these conditions are major causes of morbidity and mortality worldwide and are characterized by chronic inflammation, varying degrees of airway obstruction, and tissue remodeling, which can lead to severe respiratory failure. Despite their clinical importance, no effective biomarkers have been identified that reflect the pathophysiology of these diseases or can be used in personalized medicine, although detailed mechanisms have been elucidated.

Extracellular vesicles (EVs) are lipid bilayer-enclosed vesicles secreted by all types of cells, and they cannot replicate on their own [1]. They are known to play crucial roles as intercellular communication agents in pathophysiological processes. EVs contain lipids, proteins, and nucleic acids. Based on differences in size and production mechanisms, there are various classifications of EVs. Exosomes are vesicles derived from endosomal membranes and are released through multivesicular body (MVB) [1]. In contrast, ectosomes are vesicles the directly bud from the plasma membrane. With respect to the size of EVs, small EVs (50–150 nm in diameter) including exosomes are the most abundant in the body fluids, whereas large EVs (≥ 1 μm in diameter) such as apoptotic bodies are present in smaller numbers [2]. These vesicles are released into various body fluids, including blood, urine, saliva, and breast milk, and are taken up by target cells through direct membrane fusion, ligand-receptor interactions, or endocytosis [3]. Most of circulating EVs are thought to be cleared by uptake in target organs [3].

Recent advancements in EV research have opened new opportunities for elucidating the pathogenesis of various diseases, including malignancies and inflammatory conditions, and for discovering novel biomarkers. The regulation of EV biosynthesis and cargo selection is crucial for identifying pathology-specific profiles essential for clinical applications [4, 5]. Among the various omics approaches, proteomics is directly related to phenotypes, and proteins have been most frequently used as biomarkers in clinical practice [6]. Particularly in cancer research, proteins of blood EVs, which include plasma or serum EVs, are being actively explored as promising tools for liquid biopsy, offering non-invasive methods for diagnosis and prognostic evaluation [7–9].

Lungs are the largest organ in the body with extensive blood circulation; therefore, blood EV proteomics is a valuable approach for biomarker discovery and understanding the pathogenesis of inflammatory respiratory diseases. This review details the technical advancements and significant findings in blood EV proteomics research within the context of inflammatory respiratory diseases and discusses their potential clinical applications and prospects (Fig. 1).Fig. 1 Workflow for proteomics studies in inflammatory lung diseases using blood EVs. First, from blood samples collected from patients and control cases, EVs are extracted. Proteomics, mainly mass spectrometry-based proteomics, is conducted on these EV samples. The obtained proteomic data are compared between patients and controls to identify candidate biomarkers or key molecules associated with the diseases. The results are validated in an independent cohort to confirm the promising candidates. Subsequent studies include the validation of these candidates using clinically applicable measurement systems and biological analyses to elucidate the pathophysiological mechanisms regulated by the identified molecules. Abbreviations: LC–MS/MS, liquid chromatography with tandem mass spectrometry; DIA, data independent acquisition; DDA, data dependent acquisition; MRM, multiple reaction monitoring

Proteomics technology for EVs

Recently, blood EVs have attracted considerable attention as valuable resources for biomarkers, and they can be easily and repeatedly collected from blood and, unlike plasma or serum, are protected from degradation by proteases, retaining disease-related molecular information [1, 10]. Furthermore, EVs lack abundant proteins such as albumin and globulins, making them more suitable for deep proteomic analysis than plasma or serum [11].

Advances in proteomic techniques have been remarkable in recent years. Mass spectrometry (MS) techniques are primarily used in high-depth proteomics. Typically, mixtures of peptide fragments are introduced into an analytical system, liquid chromatography/mass spectrometry (LC–MS/MS), in which a tandem mass spectrometer is connected to a low-flow liquid chromatograph [12]. Conventional peptide measurements rely on the technique of data-dependent acquisition (DDA), which automatically selects ionized peptides for fragmentation based on the detection intensity of each ion [13]. This method can be used to identify numerous proteins.

Recently, however, a new MS mode, data-independent acquisition (DIA), has been developed. In this method, ions within a set m/z range are simultaneously subjected to fragmentation while shifting the m/z window rather than being selected on an ionized peptide-by-peptide basis. This revolutionary method, also known as next-generation proteomics, enables comprehensive protein identification at greater depths with higher precision than DDA [14, 15].

By utilizing blood EVs and analyzing them using state-of-the-art proteomic techniques, it has become possible to measure a wide range of pathophysiology-related proteins, even in trace amounts. Consequently, biomarker research for various diseases, particularly cancer, has advanced, and a new understanding of their pathogenesis has been achieved. This strategy is also being applied in research on inflammatory respiratory diseases.

Blood EV proteomics in ILDs

Interstitial lung diseases (ILDs) comprise a category of disorders marked by inflammation and fibrosis of the lung interstitium, leading to reduced pulmonary function. ILDs include various underlying conditions, such as idiopathic pulmonary fibrosis (IPF), connective tissue disease-related ILD, and chronic hypersensitivity pneumonitis. Increasing attention is being given to a subset of these diseases that progress to a phenotype characterized by extensive fibrosis, known as progressive fibrosing ILD (PF-ILD) [16] or progressive pulmonary fibrosis (PPF) [17]. It is estimated that 30–40% of ILD cases develop progressive fibrosis with a poor prognosis, exhibiting a median survival of 2.5–3.5 years [18].

The role of EVs in fibrosis pathogenesis has attracted considerable attention. For example, WNT5A-positive EVs, produced predominantly by fibroblasts, promote fibrosis [19]. Aging fibroblasts induce fibroblast infiltration via fibronectin in EVs [20]. Proteomic analyses of fibroblast-derived EVs from patients with IPF have revealed a higher number of proteins involved in fibrogenic processes than those from healthy individuals [21]. While EVs from alveolar epithelial cells have been implicated in fibroblast activation [22], EVs from the airway epithelial cells of patients with IPF promote epithelial cell senescence and induce inflammation [23].

Therefore, blood EV proteomics holds promise for the identification of key disease molecules and biomarkers (Table 1). For example, Adduri et al. performed LC–MS/MS proteomic analysis on 163 plasma EV samples, including those from patients with IPF, CHP, and NSIP, and healthy controls, identifying EV proteins SFTPB, ALDOA, HMGB1, CALML5, and TLN1 as useful markers for distinguishing IPF from other ILDs [24]. In another study, serum EVs from patients with ILD exhibiting progressive fibrosis other than IPF were analyzed using DIA-based next-generation proteomics, revealing 2420 proteins. Among them, SFTPB is a biomarker for predicting progressive fibrosis, which was confirmed using immunohistochemical analyses of patient lung tissues. SFTPB, a pulmonary surfactant protein produced by alveolar epithelial cells, is normally shed and matures. The mature form, which is abundant in the serum, is not a reliable predictor of progressive fibrosis. However, the pro-form is secreted into EVs during fibrosis and protected from shedding, and can accurately predict progressive fibrosis [25]. Interestingly, in single-cell RNA sequencing of lung tissues of a murine model of pulmonary fibrosis, the expression of SFTPB was upregulated in alveolar epithelial cells before the fibrotic phase, suggesting that this molecule is associated with profibrotic pathophysiology. Furthermore, Bayesian network integration analysis of the serum EV proteome with clinical data revealed IPF-specific network including modules related to TGF-β signaling and complement pathways, when comparing patients with IPF to healthy subjects [26]. Table 1 Blood EV proteomics for inflammatory respiratory diseases

References	Disease	Technology	MS mode	Feature	Biomarkers	Disease severity predicted by the biomarkers	
Adduri, et al. [24]	ILD	LC–MS/MS	DDA	Diagnosis for IPF	SFTPB, ALDOA, HMGB1, CALML5, and TLN1	Diagnostic/classification use	
Enomoto, et al. [25]	ILD	LC–MS/MS	DIA	Diagnosis for PPF	SFTPB	Unfavorable	
Tomoto, et al. [26]	ILD	LC–MS/MS	DIA	Estimation of IPF‑specific protein network	-	-	
Yoshimura, et al. [37]	BA	LC–MS/MS	DIA	Diagnosis for eosinophilic BA	Gal-10	Unfavorable	
Koba, et al. [45]	COPD	LC–MS/MS	DDA	Diagnosis for COPD	Fibulin-3	Unfavorable	
Jung, et al. [46]	COPD	EV array analysis		Diagnosis for acute exacerbation of COPD	CD45 and CD28	Diagnostic/classification use	
Mao, et al. [60]	COVID-19	LC–MS/MS	DIA	Characteristics and residual traces of recovered COVID-19 patients	Proteins associated with coagulation activity, inflammatory reaction, immune response, and low organ function	Diagnostic/classification use	
Krishnamachary, et al. [62]	COVID-19	PEA	-	Diagnosis of severe patients	TF, CD163, and EN-RAGE	Unfavorable	
Fujita, et al. [61]	COVID-19	LC–MS/MS	DDA	Predictive biomarkers of severe patients	COPB2	Favorable	
Lam, et al. [49]	COVID-19	LC–MS/MS	DDA	Proteomics change of different temporal stages of COVID-19	C1r, C1s	Diagnostic/classification use	
Kawasaki, et al. [63]	COVID-19	LC–MS/MS	DIA	Predictive biomarkers of refractory patients	MACROH2A1	Unfavorable	
Mehaffy, et al. [70]	M. tuberculosis	MRM-MS	-	Identification of peptides associated with LTBI	glutamine synthetase (GlnA1) enzyme	Diagnostic/classification use	
Cheng, et al. [71]	Pediatric pneumonia	LC–MS/MS	DDA	Immune signatures of children with pneumonia	SERPINA1, ITIH4, IGLV6-57, HIST2H3A, HIST1H4, HIST1H2BL, COL1A1, ANXA2, COL2A1, ACAN, DSP, XP32, DSC1, HAPLN1, and DSG1	Diagnostic/classification use	
Abbreviations: ILD interstitial lung disease, IPF idiopathic pulmonary fibrosis, PPF progressive pulmonary fibrosis, BA bronchial asthma, COPD chronic obstructive pulmonary disease, LTBI latent tuberculosis infection, LC–MS/MS liquid chromatography with tandem mass spectrometry, MS mass spectrometry, PEA proximity extension analysis, DIA data-independent acquisition, DDA data-dependent acquisition

Despite the potential of blood EV proteomics, the field remains in its infancy, and relatively fewer studies have focused on miRNAs [27]. This area of research holds substantial promise for further development, particularly when considering the heterogeneity of ILDs. Identifying molecules that facilitate patient stratification and control of common pathological processes, such as PPF, remains a critical issue.

Blood EV proteomics in BA

BA is a common chronic allergic airway disease characterized by reversible airflow limitation in the peripheral airways, leading to clinical symptoms such as wheezing and dyspnea [28]. Approximately 300 million patients suffer from asthma worldwide [29], with asthma-related deaths reported to be approximately 200,000 per year [30], making it a major global health challenge. The pathogenesis of BA involves immune cells, such as eosinophils, Th2 lymphocytes, and type 2 innate lymphocytes, as well as non-immune cells including airway epithelial cells and smooth muscle cells.

Cytokine-mediated interactions, including those between TSLP, interleukin (IL)-13, IL-33, and IL-5, play crucial roles in promoting disease; these cytokines are targets for biologic agents [31, 32]. The significance of EVs in the pathogenesis of BA has been highlighted by numerous studies. For example, eosinophil-derived EVs are released in response to inflammatory stimuli [33], dendritic cell-derived EVs promote CD4+T cell proliferation and Th2 differentiation [34], and airway epithelial cell-derived EVs can induce airway inflammation [35]. Notably, Cañas et al. conducted proteomic analysis on EVs extracted from peripheral blood eosinophils of patients with asthma and healthy subjects and demonstrated that eosinophil-derived EVs from patients with asthma promote ROS production and eosinophil migration [36].

By focusing on the proteomics of serum EVs, Yoshimura et al. identified Galectin-10 as a biomarker of eosinophilic asthma using DIA MS [37]. This protein demonstrated superior diagnostic capability compared with peripheral blood eosinophil counts and correlated with clinical parameters, such as airflow obstruction and mucus plug. Moreover, Galectin-10 released by eosinophils during EETosis has been found to correlate with the degree of EETosis in BA lung tissue and nasal mucosal tissue in chronic rhinosinusitis with nasal polyps, suggesting that Galectin-10 in EVs may reflect the pathogenesis of eosinophilic inflammation in asthma (Table 1).

Although eosinophil-derived EVs, which are crucial for the development of BA, are a rich source of biomarkers and important disease molecules, it is essential to focus on EVs derived from cells other than eosinophils to identify biomarkers and elucidate the pathophysiology of non-eosinophilic asthma in the future. Compared with eosinophilic asthma, non-eosinophilic asthma currently lacks sufficient biomarkers and therapeutic options, and the proteomics of blood EVs may offer a valuable research tool to address this unmet need.

Blood EV proteomics in COPD

COPD is a long-term lung condition marked by persistent airflow obstruction that primarily results from the prolonged inhalation of tobacco smoke. Inhalation of harmful substances induces inflammation, oxidative stress, and alveolar cell apoptosis, triggering alveolar destruction and remodeling [38]. One of the primary mechanisms by which EVs contribute to the pathogenesis of COPD involves the degradation of the extracellular matrix. Neutrophil elastase level in EVs derived from multinucleated cells is higher in the lungs of patients with COPD than in the lungs of healthy subjects, and the transfer of these EVs collected by bronchoalveolar lavage of patients with COPD to mice can induce COPD-like symptoms [39]. In addition, in vitro studies have shown that EVs released from airway epithelial cells in response to cigarette smoke exposure promote MMP-1 production via CCN1 (Cyr61) [40] and macrophages produce MMP14-rich EVs when stimulated with cigarette smoke extract [41]. EVs derived from macrophages after atmospheric fine particulate matter (PM) stimulation induce IL-6 and TNFα production in lung epithelial cells [42]. Similarly, mononuclear cells stimulated by cigarette smoke extract produce microparticles that induce proinflammatory mediators such as ICAM-1 and IL-8 in lung epithelial cells [43]. Moreover, EVs from airway epithelial cells stimulated with cigarette smoke extract have been shown to induce M1 macrophage polarization [44]. These findings suggest that EVs play a role in promoting chronic airway inflammation.

Several proteomic studies have been conducted on blood EVs in patients with COPD (Table 1). For example, Koba et al. performed a proteomic analysis of serum EVs from patients and mouse models with COPD to identify common biomarkers [45]. The authors identified Fibulin-3 as an elevated protein in patients with COPD, correlating with the extent of emphysema on CT scans and reduced pulmonary function. Notably, Fibulin-3-knockout mice spontaneously developed emphysema, suggesting that key pathological molecules were encapsulated within EVs. Distinguishing acute exacerbations of COPD (AECOPD) from bacterial pneumonia, often presenting as acute respiratory failure, is clinically challenging. Jung et al. conducted a comprehensive examination of the surface proteins on plasma EVs from patients with community-acquired pneumonia and AECOPD using protein microarrays and successfully identified CD45 and CD28 as the most useful markers for differentiation [46].

To date, blood EV omics analysis in COPD has mainly focused on miRNAs [47, 48]; however, as discussed above, substantial evidence suggests that EV proteins play a critical role in the pathogenesis of COPD. Given the lack of curative treatments for COPD, identifying molecules through blood EV proteomics that influence disease pathogenesis or serve as therapeutic targets is crucial.

Blood EV proteomics in respiratory infections

The role of EVs in the pathogenesis of respiratory infections, including viral and bacterial infections, is being increasingly recognized. In particular, the COVID-19 pandemic, which has led to numerous severe cases and deaths, has promoted extensive research on blood EV proteomics and EV involvement in disease pathogenesis.

EVs in viral infections

The involvement of EVs in COVID-19 pathogenesis has been extensively investigated. EVs derived from SARS-CoV-2-infected cells contribute to disease propagation by transporting viral particles and inflammatory molecules [49–51]. EVs from epithelial cells containing SP-C can induce chronic inflammation in the heart [52]. Moreover, endothelial cell-derived serum EVs are correlated with hospitalization mortality [53]. In immune cells, EVs from dendritic cells stimulated by viral proteins activate CD4+ and CD8+ T-cells [54], and neutrophil elastase in EVs has been reported to cause endothelial cell damage [55].

EVs are involved in the pathogenesis of other viral infections by inducing inflammation. For instance, in RS virus infection, EVs from infected epithelial cells show altered protein profiles, leading to elevated levels of chemokines including CCL20 [56]. EVs derived from infected lung epithelial cells stimulate monocytes and epithelial cells to secrete proinflammatory mediators [57]. Previous studies have suggested that EVs may have protective functions against infections. In influenza infection, EVs have a role in host defense including neutralizing the virus [58]. Additionally, the uptake of macrophage-derived EVs by alveolar epithelial cells increases endosomal acidification and inhibits viral nuclear transfer and replication [59].

Most studies on blood EV proteomics in viral infections have focused on COVID-19, revealing critical insights through various proteomic methods (Table 1). Mao et al. used MS in the DIA mode to analyze plasma EVs from patients with COVID-19 in the recovery phase, identifying a total of 394 proteins, with 174 differentially expressed proteins associated with coagulation, inflammation, immune response, and organ dysfunction [60]. Similarly, Fujita et al. employed DDA mode proteomics on serum EVs from patients with COVID-19 and discovered that the protein COPB2 could diagnose severe illness post-admission with high accuracy (AUC = 1.0 in the discovery set, AUC = 0.85 in the validation set) [61]. These findings underscore the utility of the DIA and DDA methods in identifying critical proteins involved in COVID-19 pathogenesis. In addition to these methods, Krishnamachary et al. used the proximity extension assay (PEA) on plasma EVs from 84 hospitalized patients with COVID-19 to uncover enriched pathways related to coagulation and inflammation. The authors identified EN-RAGE, TF, and IL-18R1 as proteins that strongly correlated with disease severity and length of hospitalization, suggesting that these proteins are key markers in COVID-19 pathology. Furthermore, EVs from patients with COVID-19 have been shown to induce the apoptosis of pulmonary microvascular endothelial cells in relation to disease severity, highlighting the potential of PEA in identifying biomarkers [62]. Multiomics analyses provided significant insights. Lam et al. combined DDA proteomics with lipidomics to analyze plasma EVs from patients with COVID-19 at different stages of the disease. The authors revealed enrichment of pathways involved in the complement system, coagulation cascade, and platelet activation, with decreased levels of C1r and C1s during the symptomatic phase compared to the asymptomatic phase, indicating potential biomarkers for disease progression [49]. Kawasaki et al. used DIA mode proteomics on serum EVs from patients with COVID-19 of varying severities and combined it with single-cell analysis of peripheral blood mononuclear cells. The authors identified a group of macrophage-related proteins enriched in refractory cases. Notably, they found that MACROH2A1, which was induced in monocytes and macrophages, is a biomarker for refractory COVID-19 pneumonia that is resistant to corticosteroids, emphasizing the value of integrating multi-omics approaches to understand complex disease mechanisms [63].

EVs in bacterial infections

EVs can mediate pathogen transmission during bacterial infections. For example, in Legionella infection, EVs from infected cells can spread to other cells and promote the expression of inflammatory cytokines [64]. In tuberculosis, antigen-presenting cells take up EVs containing mycobacterial antigens, thereby activating the acquired immune system [65–67]. EVs also directly activate the immune system and induce inflammation; in Staphylococcus aureus infections, neutrophil-derived EVs induce IL-6 and IL-1β production by macrophages [68]. In Listeria infections, EVs from infected dendritic cells induce stronger anti-pathogenic responses in recipient immature dendritic cells than those from uninfected cells [69]. These studies collectively highlight the pivotal role of EVs in bacterial infections, in not only facilitating pathogen transmission but also modulating immune responses and inflammation.

In the blood EV proteomics of bacterial infections (Table 1), Mehaffy et al. performed targeted proteomics (MRM-MS) on sera from 74 patients with latent tuberculosis infection (LTBI) and 29 controls, detecting Mycobacterium tuberculosis-derived peptides in 95% of patients with LTBI [70]. Another study compared the serum EV proteomes of six pediatric patients with pneumonia with those of healthy controls, revealing host response features such as neutrophil activation and complement regulation [71].

In summary, EVs play a significant role in immune response and tissue damage in infectious diseases by transporting either pathogens or derived proteins and inducing inflammation. Numerous molecules regulating pathological conditions have been identified through blood EV proteomics, making it one of the most active research areas outside oncology. Identifying biomarkers and therapeutic targets for clinical applications is highly anticipated.

Conclusions and perspectives

The proteomics of blood EVs in inflammatory lung diseases can reveal valuable biomarkers, including key molecules related to disease pathogenesis, likely due to the functional characteristics of EVs and their advantages over serum or plasma as proteomic samples. Given the large volume of circulating blood passing through the lungs, organ-specific EVs may be more abundant in the bloodstream. EVs contain not only biomarkers but also crucial molecules that regulate pathological conditions; for instance, knockout mice lacking such molecules may display disease phenotypes [45]. Consequently, therapies targeting EV proteins can be developed using these proteins as companion biomarkers.

Several limitations of blood EV proteomics research persist. First, EV proteins are not readily captured in clinical practice using tools such as ELISA kits, and the identified biomarker molecules do not immediately translate into clinical applications. Developing assay systems for the direct detection of EV proteins is crucial, and progress has been made in this area [72, 73]. If trends in EV protein variations mirror those of whole serum or plasma proteins, these findings could be easily applied in clinical settings, as similar trends can be reproduced using ELISA on serum samples [74]. Second, the lack of standardized EV extraction protocols, immature proteomic analysis systems, and interpretation methods, along with developing techniques to improve the reproducibility of MS results, remain major challenges that must be addressed by future studies [6, 75–77]. To mitigate these issues, validating exploratory studies with additional cohorts is desirable.

In summary, blood EV proteomics for inflammatory respiratory diseases represents a promising research approach with potential applications in liquid biopsy and discovering novel therapies. The important findings discussed in this review highlight the significance of this approach. Further technological advances, such as the development of more reproducible proteomic assays and direct measurement systems for EVs, will contribute to progress in this field.

Abbreviations

BA Bronchial asthma

COPD Chronic obstructive pulmonary disease

DDA Data-dependent acquisition

DIA Data-independent acquisition

EV Extracellular vesicle

ILD Interstitial lung disease

IPF Idiopathic pulmonary fibrosis

LC–MS/MS Liquid chromatography with tandem mass spectrometry

LTBI Latent tuberculosis infection

MS Mass spectrometry

PEA Proximity extension assay

PF-ILD Progressive-fibrosing interstitial lung diseases

PPF Progressive pulmonary fibrosis

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing. We also thank Kenichi Mogi for the contributions to figure illustrations.

Authors’ contributions

T.K. wrote and Y.T. proofread the manuscript. Y.T. and A.K. supervised the study. The authors read and approved the final manuscript.

Funding

This study was supported by Cabinet Office of Japan Government for the Public/Private R&D Investment Strategic Expansion PrograM (PRISM); the Japan Agency for Medical Research and Development (AMED) (JP223fa627002 to A.K.); the Japan Society for the Promotion of Science (JSPS) KAKENHI (24K19241 to T.K., JP19K08650 and 22K08283 to Y.T., JP18H05282 to A.K.); Japan Intractable Diseases (Nanbyo) Research Foundation (2023B02 to T.K.); the Japanese Respiratory Society Research Grants Program (to T.K.); an Uehara Memorial Foundation grant (to Y.T.); a Japanese Respiratory Foundation grant (to Y.T.); and the All-Osaka U Research in “The Nippon Foundation–Osaka University Project for Infectious Disease Prevention.”

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Welsh JA Goberdhan DCI O’Driscoll L Buzas EI Blenkiron C Bussolati B Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches J Extracell Vesicles 2024 13 e12404 10.1002/jev2.12404 38326288
Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.38326288
2. Buzas EI The roles of extracellular vesicles in the immune system Nat Rev Immunol 2023 23 236 250 10.1038/s41577-022-00763-8 35927511
Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23:236–50.35927511
3. Yáñez-Mó M Siljander PR Andreu Z Zavec AB Borràs FE Buzas EI Biological properties of extracellular vesicles and their physiological functions J Extracell Vesicles 2015 4 27066 10.3402/jev.v4.27066 25979354
Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.25979354
4. Xu R Greening DW Zhu HJ Takahashi N Simpson RJ Extracellular vesicle isolation and characterization: toward clinical application J Clin Invest 2016 126 1152 1162 10.1172/JCI81129 27035807
Xu R, Greening DW, Zhu HJ, Takahashi N, Simpson RJ. Extracellular vesicle isolation and characterization: toward clinical application. J Clin Invest. 2016;126:1152–62.27035807
5. Dixson A Dawson TR Di Vizio D Weaver AM Context-specific regulation of extracellular vesicle biogenesis and cargo selection Nat Rev Mol Cell Biol 2023 24 454 476 10.1038/s41580-023-00576-0 36765164
Dixson A, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular vesicle biogenesis and cargo selection. Nat Rev Mol Cell Biol. 2023;24:454–76.36765164
6. Ding Z Wang N Ji N Chen ZS Proteomics technologies for cancer liquid biopsies Mol Cancer 2022 21 53 10.1186/s12943-022-01526-8 35168611
Ding Z, Wang N, Ji N, Chen ZS. Proteomics technologies for cancer liquid biopsies. Mol Cancer. 2022;21:53.35168611
7. Hoshino A Kim HS Bojmar L Gyan KE Cioffi M Hernandez J Extracellular vesicle and particle biomarkers define multiple human cancers Cell 2020 182 1044 61.e18 10.1016/j.cell.2020.07.009 32795414
Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182:1044-61.e18.32795414
8. Jo A Green A Medina JE Iyer S Ohman AW McCarthy ET Inaugurating high-throughput profiling of extracellular vesicles for earlier ovarian cancer detection Adv Sci Weinh Baden-Wurtt Ger 2023 10 e2301930
Jo A, Green A, Medina JE, Iyer S, Ohman AW, McCarthy ET, et al. Inaugurating high-throughput profiling of extracellular vesicles for earlier ovarian cancer detection. Adv Sci Weinh Baden-Wurtt Ger. 2023;10:e2301930.
9. Pang B, Wang Q, Chen H, Liu Z, Han M, Gong J, et al. Proteomic identification of small extracellular vesicle proteins LAMB1 and histone H4 for prostate cancer diagnosis and risk stratification. Adv Sci Weinh Baden-Wurtt Ger. 2024;e2402509.
10. Li A Zhang T Zheng M Liu Y Chen Z Exosomal proteins as potential markers of tumor diagnosis J Hematol OncolJ Hematol Oncol 2017 10 175 10.1186/s13045-017-0542-8 29282096
Li A, Zhang T, Zheng M, Liu Y, Chen Z. Exosomal proteins as potential markers of tumor diagnosis. J Hematol OncolJ Hematol Oncol. 2017;10:175.29282096
11. Lässer C Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicle Expert Opin Biol Ther 2015 15 103 117 10.1517/14712598.2015.977250 25363342
Lässer C. Exosomes in diagnostic and therapeutic applications: biomarker, vaccine and RNA interference delivery vehicle. Expert Opin Biol Ther. 2015;15:103–17.25363342
12. Cox J Mann M Quantitative, high-resolution proteomics for data-driven systems biology Annu Rev Biochem 2011 80 273 299 10.1146/annurev-biochem-061308-093216 21548781
Cox J, Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem. 2011;80:273–99.21548781
13. Michalski A Cox J Mann M More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS J Proteome Res 2011 10 1785 1793 10.1021/pr101060v 21309581
Michalski A, Cox J, Mann M. More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS/MS. J Proteome Res. 2011;10:1785–93.21309581
14. Distler U Kuharev J Navarro P Levin Y Schild H Tenzer S Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics Nat Methods 2014 11 167 170 10.1038/nmeth.2767 24336358
Distler U, Kuharev J, Navarro P, Levin Y, Schild H, Tenzer S. Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. Nat Methods. 2014;11:167–70.24336358
15. Bruderer R Bernhardt OM Gandhi T Miladinović SM Cheng LY Messner S Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues Mol Cell Proteomics MCP 2015 14 1400 1410 10.1074/mcp.M114.044305 25724911
Bruderer R, Bernhardt OM, Gandhi T, Miladinović SM, Cheng LY, Messner S, et al. Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues. Mol Cell Proteomics MCP. 2015;14:1400–10.25724911
16. Flaherty KR Wells AU Cottin V Devaraj A Walsh SLF Inoue Y Nintedanib in progressive fibrosing interstitial lung diseases N Engl J Med 2019 381 1718 1727 10.1056/NEJMoa1908681 31566307
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–27.31566307
17. Raghu G Remy-Jardin M Richeldi L Thomson CC Inoue Y Johkoh T Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline Am J Respir Crit Care Med 2022 205 e18 47 10.1164/rccm.202202-0399ST 35486072
Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18-47.35486072
18. Oldham JM Lee CT Wu Z Bowman WS Pugashetti JV Dao N Lung function trajectory in progressive fibrosing interstitial lung disease Eur Respir J 2022 59 2101396 10.1183/13993003.01396-2021 34737223
Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022;59:2101396.34737223
19. Martin-Medina A Lehmann M Burgy O Hermann S Baarsma HA Wagner DE increased extracellular vesicles mediate WNT5A signaling in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 2018 198 1527 1538 10.1164/rccm.201708-1580OC 30044642
Martin-Medina A, Lehmann M, Burgy O, Hermann S, Baarsma HA, Wagner DE, et al. increased extracellular vesicles mediate WNT5A signaling in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;198:1527–38.30044642
20. Chanda D Otoupalova E Hough KP Locy ML Bernard K Deshane JS Fibronectin on the surface of extracellular vesicles mediates fibroblast invasion Am J Respir Cell Mol Biol 2019 60 279 288 10.1165/rcmb.2018-0062OC 30321056
Chanda D, Otoupalova E, Hough KP, Locy ML, Bernard K, Deshane JS, et al. Fibronectin on the surface of extracellular vesicles mediates fibroblast invasion. Am J Respir Cell Mol Biol. 2019;60:279–88.30321056
21. Velázquez-Enríquez JM Santos-Álvarez JC Ramírez-Hernández AA Reyes-Jiménez E López-Martínez A Pina-Canseco S Proteomic analysis reveals key proteins in extracellular vesicles cargo associated with idiopathic pulmonary fibrosis in vitro Biomedicines 2021 9 1058 10.3390/biomedicines9081058 34440261
Velázquez-Enríquez JM, Santos-Álvarez JC, Ramírez-Hernández AA, Reyes-Jiménez E, López-Martínez A, Pina-Canseco S, et al. Proteomic analysis reveals key proteins in extracellular vesicles cargo associated with idiopathic pulmonary fibrosis in vitro. Biomedicines. 2021;9:1058.34440261
22. Li N Li K Zhao W Wang Y Xu C Wang Q Small extracellular vesicles from irradiated lung epithelial cells promote the activation of fibroblasts in pulmonary fibrosis Int J Radiat Biol 2024 100 268 280 10.1080/09553002.2023.2263550 37747344
Li N, Li K, Zhao W, Wang Y, Xu C, Wang Q, et al. Small extracellular vesicles from irradiated lung epithelial cells promote the activation of fibroblasts in pulmonary fibrosis. Int J Radiat Biol. 2024;100:268–80.37747344
23. Asghar S Monkley S Smith DJF Hewitt RJ Grime K Murray LA Epithelial senescence in idiopathic pulmonary fibrosis is propagated by small extracellular vesicles Respir Res 2023 24 51 10.1186/s12931-023-02333-5 36788603
Asghar S, Monkley S, Smith DJF, Hewitt RJ, Grime K, Murray LA, et al. Epithelial senescence in idiopathic pulmonary fibrosis is propagated by small extracellular vesicles. Respir Res. 2023;24:51.36788603
24. Adduri RSR Cai K Velasco-Alzate K Vasireddy R Miller JW de Frías SP Plasma extracellular vesicle proteins as promising noninvasive biomarkers for diagnosis of idiopathic pulmonary fibrosis J Extracell Biol 2023 2 e98 10.1002/jex2.98 38939072
Adduri RSR, Cai K, Velasco-Alzate K, Vasireddy R, Miller JW, de Frías SP, et al. Plasma extracellular vesicle proteins as promising noninvasive biomarkers for diagnosis of idiopathic pulmonary fibrosis. J Extracell Biol. 2023;2:e98.38939072
25. Enomoto T Shirai Y Takeda Y Edahiro R Shichino S Nakayama M SFTPB in serum extracellular vesicles as a biomarker of progressive pulmonary fibrosis JCI Insight 2024 9 e177937 10.1172/jci.insight.177937 38855869
Enomoto T, Shirai Y, Takeda Y, Edahiro R, Shichino S, Nakayama M, et al. SFTPB in serum extracellular vesicles as a biomarker of progressive pulmonary fibrosis. JCI Insight. 2024;9:e177937.38855869
26. Tomoto M Mineharu Y Sato N Tamada Y Nogami-Itoh M Kuroda M Idiopathic pulmonary fibrosis-specific Bayesian network integrating extracellular vesicle proteome and clinical information Sci Rep 2024 14 1315 10.1038/s41598-023-50905-8 38225283
Tomoto M, Mineharu Y, Sato N, Tamada Y, Nogami-Itoh M, Kuroda M, et al. Idiopathic pulmonary fibrosis-specific Bayesian network integrating extracellular vesicle proteome and clinical information. Sci Rep. 2024;14:1315.38225283
27. d’Alessandro M Bergantini L Bargagli E Vidal S Extracellular vesicles in pulmonary fibrosis models and biological fluids of interstitial lung disease patients: a scoping review Life Basel Switz 2021 11 1401
d’Alessandro M, Bergantini L, Bargagli E, Vidal S. Extracellular vesicles in pulmonary fibrosis models and biological fluids of interstitial lung disease patients: a scoping review. Life Basel Switz. 2021;11:1401.
28. Global Initiative for Asthma – GINA. 2024 GINA Main Report. Available from: https://ginasthma.org/2024-report/.
29. Dharmage SC Perret JL Custovic A Epidemiology of asthma in children and adults Front Pediatr 2019 7 246 10.3389/fped.2019.00246 31275909
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246.31275909
30. Ebmeier S Thayabaran D Braithwaite I Bénamara C Weatherall M Beasley R Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012) Lancet Lond Engl 2017 390 935 945 10.1016/S0140-6736(17)31448-4
Ebmeier S, Thayabaran D, Braithwaite I, Bénamara C, Weatherall M, Beasley R. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993–2012). Lancet Lond Engl. 2017;390:935–45.
31. Brusselle G Bracke K Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease Ann Am Thorac Soc 2014 11 S322 S328 10.1513/AnnalsATS.201403-118AW 25525740
Brusselle G, Bracke K. Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:S322–8.25525740
32. Busse WW Kraft M Rabe KF Deniz Y Rowe PJ Ruddy M Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation Eur Respir J 2021 58 2003393 10.1183/13993003.03393-2020 33542055
Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe PJ, Ruddy M, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58:2003393.33542055
33. Akuthota P Carmo LAS Bonjour K Murphy RO Silva TP Gamalier JP Extracellular microvesicle production by human eosinophils activated by “inflammatory” stimuli Front Cell Dev Biol 2016 4 117 10.3389/fcell.2016.00117 27833910
Akuthota P, Carmo LAS, Bonjour K, Murphy RO, Silva TP, Gamalier JP, et al. Extracellular microvesicle production by human eosinophils activated by “inflammatory” stimuli. Front Cell Dev Biol. 2016;4:117.27833910
34. Huang L Zhang X Wang M Chen Z Yan Y Gu W Exosomes from thymic stromal lymphopoietin-activated dendritic cells promote Th2 differentiation through the OX40 ligand Pathobiology 2019 86 111 117 10.1159/000493013 30408778
Huang L, Zhang X, Wang M, Chen Z, Yan Y, Gu W, et al. Exosomes from thymic stromal lymphopoietin-activated dendritic cells promote Th2 differentiation through the OX40 ligand. Pathobiology. 2019;86:111–7.30408778
35. Ax E Jevnikar Z Cvjetkovic A Malmhäll C Olsson H Rådinger M T2 and T17 cytokines alter the cargo and function of airway epithelium-derived extracellular vesicles Respir Res 2020 21 155 10.1186/s12931-020-01402-3 32560723
Ax E, Jevnikar Z, Cvjetkovic A, Malmhäll C, Olsson H, Rådinger M, et al. T2 and T17 cytokines alter the cargo and function of airway epithelium-derived extracellular vesicles. Respir Res. 2020;21:155.32560723
36. Cañas JA Sastre B Mazzeo C Fernández-Nieto M Rodrigo-Muñoz JM González-Guerra A Exosomes from eosinophils autoregulate and promote eosinophil functions J Leukoc Biol 2017 101 1191 1199 10.1189/jlb.3AB0516-233RR 28096299
Cañas JA, Sastre B, Mazzeo C, Fernández-Nieto M, Rodrigo-Muñoz JM, González-Guerra A, et al. Exosomes from eosinophils autoregulate and promote eosinophil functions. J Leukoc Biol. 2017;101:1191–9.28096299
37. Yoshimura H Takeda Y Shirai Y Yamamoto M Nakatsubo D Amiya S Galectin-10 in serum extracellular vesicles reflects asthma pathophysiology J Allergy Clin Immunol 2024 153 1268 1281 10.1016/j.jaci.2023.12.030 38551536
Yoshimura H, Takeda Y, Shirai Y, Yamamoto M, Nakatsubo D, Amiya S, et al. Galectin-10 in serum extracellular vesicles reflects asthma pathophysiology. J Allergy Clin Immunol. 2024;153:1268–81.38551536
38. Tuder RM Petrache I Pathogenesis of chronic obstructive pulmonary disease J Clin Invest 2012 122 2749 2755 10.1172/JCI60324 22850885
Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122:2749–55.22850885
39. Genschmer KR Russell DW Lal C Szul T Bratcher PE Noerager BD Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung Cell 2019 176 113 26.e15 10.1016/j.cell.2018.12.002 30633902
Genschmer KR, Russell DW, Lal C, Szul T, Bratcher PE, Noerager BD, et al. Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung. Cell. 2019;176:113-26.e15.30633902
40. Moon HG Kim SH Gao J Quan T Qin Z Osorio JC CCN1 secretion and cleavage regulate the lung epithelial cell functions after cigarette smoke Am J Physiol Lung Cell Mol Physiol 2014 307 L326 L337 10.1152/ajplung.00102.2014 24973403
Moon HG, Kim SH, Gao J, Quan T, Qin Z, Osorio JC, et al. CCN1 secretion and cleavage regulate the lung epithelial cell functions after cigarette smoke. Am J Physiol Lung Cell Mol Physiol. 2014;307:L326–37.24973403
41. Li CJ Liu Y Chen Y Yu D Williams KJ Liu ML Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke Am J Pathol 2013 182 1552 1562 10.1016/j.ajpath.2013.01.035 23499464
Li CJ, Liu Y, Chen Y, Yu D, Williams KJ, Liu ML. Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke. Am J Pathol. 2013;182:1552–62.23499464
42. Martin PJ Héliot A Trémolet G Landkocz Y Dewaele D Cazier F Cellular response and extracellular vesicles characterization of human macrophages exposed to fine atmospheric particulate matter Environ Pollut 2019 254 Pt A 112933 10.1016/j.envpol.2019.07.101 31382213
Martin PJ, Héliot A, Trémolet G, Landkocz Y, Dewaele D, Cazier F, et al. Cellular response and extracellular vesicles characterization of human macrophages exposed to fine atmospheric particulate matter. Environ Pollut. 2019;254(Pt A):112933.31382213
43. Cordazzo C Petrini S Neri T Lombardi S Carmazzi Y Pedrinelli R Rapid shedding of proinflammatory microparticles by human mononuclear cells exposed to cigarette smoke is dependent on Ca2+ mobilization Inflamm Res 2014 63 539 547 10.1007/s00011-014-0723-7 24599284
Cordazzo C, Petrini S, Neri T, Lombardi S, Carmazzi Y, Pedrinelli R, et al. Rapid shedding of proinflammatory microparticles by human mononuclear cells exposed to cigarette smoke is dependent on Ca2+ mobilization. Inflamm Res. 2014;63:539–47.24599284
44. Wang L Chen Q Yu Q Xiao J Zhao H Cigarette smoke extract-treated airway epithelial cells-derived exosomes promote M1 macrophage polarization in chronic obstructive pulmonary disease Int Immunopharmacol 2021 96 107700 10.1016/j.intimp.2021.107700 34000706
Wang L, Chen Q, Yu Q, Xiao J, Zhao H. Cigarette smoke extract-treated airway epithelial cells-derived exosomes promote M1 macrophage polarization in chronic obstructive pulmonary disease. Int Immunopharmacol. 2021;96:107700.34000706
45. Koba T Takeda Y Narumi R Shiromizu T Nojima Y Ito M Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres ERJ Open Res 2021 7 00658 2020 10.1183/23120541.00658-2020 33778046
Koba T, Takeda Y, Narumi R, Shiromizu T, Nojima Y, Ito M, et al. Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres. ERJ Open Res. 2021;7:00658–2020.33778046
46. Jung AL, Møller Jørgensen M, Bæk R, Griss K, Han M, Auf Dem Brinke K, et al. Surface proteome of plasma extracellular vesicles as biomarkers for pneumonia and acute exacerbation of chronic obstructive pulmonary disease. J Infect Dis. 2020;221:325-35.
47. Sundar IK Li D Rahman I Small RNA-sequence analysis of plasma-derived extracellular vesicle miRNAs in smokers and patients with chronic obstructive pulmonary disease as circulating biomarkers J Extracell Vesicles 2019 8 1684816 10.1080/20013078.2019.1684816 31762962
Sundar IK, Li D, Rahman I. Small RNA-sequence analysis of plasma-derived extracellular vesicle miRNAs in smokers and patients with chronic obstructive pulmonary disease as circulating biomarkers. J Extracell Vesicles. 2019;8:1684816.31762962
48. Shen Y Wang L Wu Y Ou Y Lu H Yao X A novel diagnostic signature based on three circulating exosomal mircoRNAs for chronic obstructive pulmonary disease Exp Ther Med 2021 22 717 10.3892/etm.2021.10149 34007326
Shen Y, Wang L, Wu Y, Ou Y, Lu H, Yao X. A novel diagnostic signature based on three circulating exosomal mircoRNAs for chronic obstructive pulmonary disease. Exp Ther Med. 2021;22:717.34007326
49. Lam SM Zhang C Wang Z Ni Z Zhang S Yang S A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19 Nat Metab 2021 3 909 922 10.1038/s42255-021-00425-4 34158670
Lam SM, Zhang C, Wang Z, Ni Z, Zhang S, Yang S, et al. A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19. Nat Metab. 2021;3:909–22.34158670
50. Troyer Z Alhusaini N Tabler CO Sweet T de Carvalho KIL Schlatzer DM Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies J Extracell Vesicles 2021 10 e12112 10.1002/jev2.12112 34188786
Troyer Z, Alhusaini N, Tabler CO, Sweet T, de Carvalho KIL, Schlatzer DM, et al. Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies. J Extracell Vesicles. 2021;10:e12112.34188786
51. Berry F Morin-Dewaele M Majidipur A Jamet T Bartier S Ignjatovic E Proviral role of human respiratory epithelial cell-derived small extracellular vesicles in SARS-CoV-2 infection J Extracell Vesicles 2022 11 e12269 10.1002/jev2.12269 36271885
Berry F, Morin-Dewaele M, Majidipur A, Jamet T, Bartier S, Ignjatovic E, et al. Proviral role of human respiratory epithelial cell-derived small extracellular vesicles in SARS-CoV-2 infection. J Extracell Vesicles. 2022;11:e12269.36271885
52. Rudiansyah M Terefe EM Opulencia MJC Abdelbasset WK Bokov DO El-Sehrawy AA Type 2 alveolar epithelial cell-derived circulating extracellular vesicle-encapsulated surfactant protein C as a mediator of cardiac inflammation in COVID-19 Inflamm Res Off J Eur Histamine Res Soc Al 2022 71 1003 1009
Rudiansyah M, Terefe EM, Opulencia MJC, Abdelbasset WK, Bokov DO, El-Sehrawy AA, et al. Type 2 alveolar epithelial cell-derived circulating extracellular vesicle-encapsulated surfactant protein C as a mediator of cardiac inflammation in COVID-19. Inflamm Res Off J Eur Histamine Res Soc Al. 2022;71:1003–9.
53. Mezine F Guerin CL Philippe A Gendron N Soret L Sanchez O Increased circulating CD62E+ endothelial extracellular vesicles predict severity and in-hospital mortality of COVID-19 patients Stem Cell Rev Rep 2023 19 114 119 10.1007/s12015-022-10446-5 35982357
Mezine F, Guerin CL, Philippe A, Gendron N, Soret L, Sanchez O, et al. Increased circulating CD62E+ endothelial extracellular vesicles predict severity and in-hospital mortality of COVID-19 patients. Stem Cell Rev Rep. 2023;19:114–9.35982357
54. Barnwal A Basu B Tripathi A Soni N Mishra D Banerjee A SARS-CoV-2 Spike protein-activated dendritic cell-derived extracellular vesicles induce antiviral immunity in mice ACS Biomater Sci Eng 2022 8 5338 5348 10.1021/acsbiomaterials.2c01094 36445062
Barnwal A, Basu B, Tripathi A, Soni N, Mishra D, Banerjee A, et al. SARS-CoV-2 Spike protein-activated dendritic cell-derived extracellular vesicles induce antiviral immunity in mice. ACS Biomater Sci Eng. 2022;8:5338–48.36445062
55. Lascano J Oshins R Eagan C Wadood Z Qiang X Flagg T Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection PLoS ONE 2022 17 e0274427 10.1371/journal.pone.0274427 36084115
Lascano J, Oshins R, Eagan C, Wadood Z, Qiang X, Flagg T, et al. Correlation of alpha-1 antitrypsin levels and exosome associated neutrophil elastase endothelial injury in subjects with SARS-CoV2 infection. PLoS ONE. 2022;17:e0274427.36084115
56. Zhao Y Jamaluddin M Zhang Y Sun H Ivanciuc T Garofalo RP Systematic analysis of cell-type differences in the epithelial secretome reveals insights into the pathogenesis of respiratory syncytial virus-induced lower respiratory tract infections J Immunol 2017 198 3345 3364 10.4049/jimmunol.1601291 28258195
Zhao Y, Jamaluddin M, Zhang Y, Sun H, Ivanciuc T, Garofalo RP, et al. Systematic analysis of cell-type differences in the epithelial secretome reveals insights into the pathogenesis of respiratory syncytial virus-induced lower respiratory tract infections. J Immunol. 2017;198:3345–64.28258195
57. Chahar HS Corsello T Kudlicki AS Komaravelli N Casola A Respiratory syncytial virus infection changes cargo composition of exosome released from airway epithelial cells Sci Rep 2018 8 387 10.1038/s41598-017-18672-5 29321591
Chahar HS, Corsello T, Kudlicki AS, Komaravelli N, Casola A. Respiratory syncytial virus infection changes cargo composition of exosome released from airway epithelial cells. Sci Rep. 2018;8:387.29321591
58. Kesimer M Scull M Brighton B DeMaria G Burns K O’Neal W Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense FASEB J 2009 23 1858 1868 10.1096/fj.08-119131 19190083
Kesimer M, Scull M, Brighton B, DeMaria G, Burns K, O’Neal W, et al. Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. FASEB J. 2009;23:1858–68.19190083
59. Schneider DJ Smith KA Latuszek CE Wilke CA Lyons DM Penke LR Alveolar macrophage-derived extracellular vesicles inhibit endosomal fusion of influenza virus EMBO J 2020 39 e105057 10.15252/embj.2020105057 32643835
Schneider DJ, Smith KA, Latuszek CE, Wilke CA, Lyons DM, Penke LR, et al. Alveolar macrophage-derived extracellular vesicles inhibit endosomal fusion of influenza virus. EMBO J. 2020;39:e105057.32643835
60. Mao K Tan Q Ma Y Wang S Zhong H Liao Y Proteomics of extracellular vesicles in plasma reveals the characteristics and residual traces of COVID-19 patients without underlying diseases after 3 months of recovery Cell Death Dis 2021 12 541 10.1038/s41419-021-03816-3 34035220
Mao K, Tan Q, Ma Y, Wang S, Zhong H, Liao Y, et al. Proteomics of extracellular vesicles in plasma reveals the characteristics and residual traces of COVID-19 patients without underlying diseases after 3 months of recovery. Cell Death Dis. 2021;12:541.34035220
61. Fujita Y Hoshina T Matsuzaki J Yoshioka Y Kadota T Hosaka Y Early prediction of COVID-19 severity using extracellular vesicle COPB2 J Extracell Vesicles 2021 10 e12092 10.1002/jev2.12092 34122778
Fujita Y, Hoshina T, Matsuzaki J, Yoshioka Y, Kadota T, Hosaka Y, et al. Early prediction of COVID-19 severity using extracellular vesicle COPB2. J Extracell Vesicles. 2021;10:e12092.34122778
62. Krishnamachary B Cook C Kumar A Spikes L Chalise P Dhillon NK Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate with COVID-19 disease severity J Extracell Vesicles 2021 10 e12117 10.1002/jev2.12117 34262673
Krishnamachary B, Cook C, Kumar A, Spikes L, Chalise P, Dhillon NK. Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate with COVID-19 disease severity. J Extracell Vesicles. 2021;10:e12117.34262673
63. Kawasaki T Takeda Y Edahiro R Shirai Y Nogami-Itoh M Matsuki T Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19 Inflamm Regen 2022 42 53 10.1186/s41232-022-00243-5 36451245
Kawasaki T, Takeda Y, Edahiro R, Shirai Y, Nogami-Itoh M, Matsuki T, et al. Next-generation proteomics of serum extracellular vesicles combined with single-cell RNA sequencing identifies MACROH2A1 associated with refractory COVID-19. Inflamm Regen. 2022;42:53.36451245
64. Jung AL Herkt CE Schulz C Bolte K Seidel K Scheller N Legionella pneumophila infection activates bystander cells differentially by bacterial and host cell vesicles Sci Rep 2017 7 6301 10.1038/s41598-017-06443-1 28740179
Jung AL, Herkt CE, Schulz C, Bolte K, Seidel K, Scheller N, et al. Legionella pneumophila infection activates bystander cells differentially by bacterial and host cell vesicles. Sci Rep. 2017;7:6301.28740179
65. Benet S Gálvez C Drobniewski F Kontsevaya I Arias L Monguió-Tortajada M Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles J Extracell Vesicles 2021 10 e12046 10.1002/jev2.12046 33489013
Benet S, Gálvez C, Drobniewski F, Kontsevaya I, Arias L, Monguió-Tortajada M, et al. Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. J Extracell Vesicles. 2021;10:e12046.33489013
66. Ramachandra L Qu Y Wang Y Lewis CJ Cobb BA Takatsu K Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation Infect Immun 2010 78 5116 5125 10.1128/IAI.01089-09 20837713
Ramachandra L, Qu Y, Wang Y, Lewis CJ, Cobb BA, Takatsu K, et al. Mycobacterium tuberculosis synergizes with ATP to induce release of microvesicles and exosomes containing major histocompatibility complex class II molecules capable of antigen presentation. Infect Immun. 2010;78:5116–25.20837713
67. Giri PK Schorey JS Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo PloS One. 2008 3 e2461 10.1371/journal.pone.0002461 18560543
Giri PK, Schorey JS. Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PloS One. 2008;3:e2461.18560543
68 Allen ER Lempke SL Miller MM Bush DM Braswell BG Estes CL Effect of extracellular vesicles from S. aureus-challenged human neutrophils on macrophages J Leukoc Biol. 2020 108 1841 50 10.1002/JLB.3AB0320-156R 32450612
Allen ER, Lempke SL, Miller MM, Bush DM, Braswell BG, Estes CL, et al. Effect of extracellular vesicles from S. aureus-challenged human neutrophils on macrophages. J Leukoc Biol. 2020;108:1841–50.32450612
69. Izquierdo-Serrano R Fernández-Delgado I Moreno-Gonzalo O Martín-Gayo E Calzada-Fraile D Ramírez-Huesca M Extracellular vesicles from Listeria monocytogenes-infected dendritic cells alert the innate immune response Front Immunol 2022 13 946358 10.3389/fimmu.2022.946358 36131943
Izquierdo-Serrano R, Fernández-Delgado I, Moreno-Gonzalo O, Martín-Gayo E, Calzada-Fraile D, Ramírez-Huesca M, et al. Extracellular vesicles from Listeria monocytogenes-infected dendritic cells alert the innate immune response. Front Immunol. 2022;13:946358.36131943
70. Mehaffy C Kruh-Garcia NA Graham B Jarlsberg LG Willyerd CE Borisov A Identification of mycobacterium tuberculosis peptides in serum extracellular vesicles from persons with latent tuberculosis infection J Clin Microbiol 2020 58 e00393 e420 10.1128/JCM.00393-20 32245831
Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, et al. Identification of mycobacterium tuberculosis peptides in serum extracellular vesicles from persons with latent tuberculosis infection. J Clin Microbiol. 2020;58:e00393-e420.32245831
71. Cheng J Ji D Yin Y Wang S Song K Pan Q Proteomic profiling of serum small extracellular vesicles reveals immune signatures of children with pneumonia Transl Pediatr 2022 11 891 908 10.21037/tp-22-134 35800266
Cheng J, Ji D, Yin Y, Wang S, Song K, Pan Q, et al. Proteomic profiling of serum small extracellular vesicles reveals immune signatures of children with pneumonia. Transl Pediatr. 2022;11:891–908.35800266
72. Iha K Tsurusawa N Tsai HY Lin MW Sonoda H Watabe S Ultrasensitive ELISA detection of proteins in separated lumen and membrane fractions of cancer cell exosomes Anal Biochem 2022 654 114831 10.1016/j.ab.2022.114831 35921878
Iha K, Tsurusawa N, Tsai HY, Lin MW, Sonoda H, Watabe S, et al. Ultrasensitive ELISA detection of proteins in separated lumen and membrane fractions of cancer cell exosomes. Anal Biochem. 2022;654:114831.35921878
73. Fujiwara K Takagi Y Tamura M Omura M Morimoto K Nakase I Ultrafast sensitivity-controlled and specific detection of extracellular vesicles using optical force with antibody-modified microparticles in a microflow system Nanoscale Horiz 2023 8 1034 1042 10.1039/D2NH00576J 37435728
Fujiwara K, Takagi Y, Tamura M, Omura M, Morimoto K, Nakase I, et al. Ultrafast sensitivity-controlled and specific detection of extracellular vesicles using optical force with antibody-modified microparticles in a microflow system. Nanoscale Horiz. 2023;8:1034–42.37435728
74. Shirai K Hikita H Sakane S Narumi R Adachi J Doi A Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients PLoS ONE 2022 17 e0271020 10.1371/journal.pone.0271020 35797333
Shirai K, Hikita H, Sakane S, Narumi R, Adachi J, Doi A, et al. Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients. PLoS ONE. 2022;17:e0271020.35797333
75. Askeland A Borup A Østergaard O Olsen JV Lund SM Christiansen G Mass-spectrometry based proteome comparison of extracellular vesicle isolation methods: comparison of ME-kit, size-exclusion chromatography, and high-speed centrifugation Biomedicines 2020 8 246 10.3390/biomedicines8080246 32722497
Askeland A, Borup A, Østergaard O, Olsen JV, Lund SM, Christiansen G, et al. Mass-spectrometry based proteome comparison of extracellular vesicle isolation methods: comparison of ME-kit, size-exclusion chromatography, and high-speed centrifugation. Biomedicines. 2020;8:246.32722497
76. Woo J Zhang Q A streamlined high-throughput plasma proteomics platform for clinical proteomics with improved proteome coverage, reproducibility, and robustness J Am Soc Mass Spectrom 2023 34 754 762 10.1021/jasms.3c00022 36975161
Woo J, Zhang Q. A streamlined high-throughput plasma proteomics platform for clinical proteomics with improved proteome coverage, reproducibility, and robustness. J Am Soc Mass Spectrom. 2023;34:754–62.36975161
77. Tian S Zhan D Yu Y Wang Y Liu M Tan S Quartet protein reference materials and datasets for multi-platform assessment of label-free proteomics Genome Biol 2023 24 202 10.1186/s13059-023-03048-y 37674236
Tian S, Zhan D, Yu Y, Wang Y, Liu M, Tan S, et al. Quartet protein reference materials and datasets for multi-platform assessment of label-free proteomics. Genome Biol. 2023;24:202.37674236
